Secretomic analysis of large cell lung cancer cell lines using two-dimensional gel electrophoresis coupled to mass spectrometry.

The secretome of cancer cells is a valuable source of biomarkers that can ultimately reach the serum or other body fluids. Cancer biomarkers can facilitate early diagnosis and monitoring of the disease, contribute to our understanding of tumor biology, and support the development of more efficient therapies. Recently, high-throughput proteomic analysis of the conditioned media of cancer cell lines has shown potential to identify novel biomarkers in cancer. We used two-dimensional gel electrophoresis coupled to liquid chromatography tandem mass spectrometry to identify the secretome of the large cell lung cancer cell lines QU-DB and Mehr-80, which they were established from a Canadian and a Persian patient, respectively. A total of 130 distinct protein species were identified. Of these, 124 were previously found in serum or other body fluids, the membrane compartment or conditioned media of other cancer cell lines. Some of the proteins that we identified, e.g. IL-6, triosephosphate isomerase, PGP9.5, α-enolase, Dickkopf-1, and peroxiredoxin-1 are known putative serum markers for lung cancer, whereas others might be candidate markers for further validation in lung cancer body fluids such as IL-25, stathmin, vimentin, peptidyl-prolyl cis-trans isomerase A, transgelin-2, and chloride intracellular channel protein 4.

[1]  Heng-tong Hu,et al.  Analysis of variabilities of serum proteomic spectra in patients with gastric cancer before and after operation. , 2006, World journal of gastroenterology.

[2]  J. Newcombe,et al.  Extracellular Matrix in Multiple Sclerosis Lesions: Fibrillar Collagens, Biglycan and Decorin are Upregulated and Associated with Infiltrating Immune Cells , 2010, Brain pathology.

[3]  Yibo Gao,et al.  Identification of Isocitrate Dehydrogenase 1 as a Potential Diagnostic and Prognostic Biomarker for Non-small Cell Lung Cancer by Proteomic Analysis* , 2011, Molecular & Cellular Proteomics.

[4]  S. Hirohashi,et al.  Expression of Vimentin in Surgically Resected Adenocarcinomas and Large Cell Carcinomas of Lung , 1986, The American journal of surgical pathology.

[5]  M. Reymond,et al.  Protein Expression in Human Non-Small Cell Lung Cancer: A Systematic Database , 2009, Pathobiology.

[6]  Kaitai Zhang,et al.  [ENO1 protein levels in the tumor tissues and circulating plasma samples of non-small cell lung cancer patients]. , 2010, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

[7]  Maria P. Pavlou,et al.  The cancer cell secretome: a good source for discovering biomarkers? , 2010, Journal of proteomics.

[8]  Mu Wang,et al.  Serum proteomics and biomarker discovery across the spectrum of nonalcoholic fatty liver disease , 2010, Hepatology.

[9]  Arne Warth,et al.  Coordinated expression of stathmin family members by far upstream sequence element-binding protein-1 increases motility in non-small cell lung cancer. , 2009, Cancer research.

[10]  T. Henkel,et al.  Identification of PSME3 as a Novel Serum Tumor Marker for Colorectal Cancer by Combining Two-dimensional Polyacrylamide Gel Electrophoresis with a Strictly Mass Spectrometry-based Approach for Data Analysis* , 2006, Molecular & Cellular Proteomics.

[11]  Y. Ikeda,et al.  Advances in our understanding of peroxiredoxin, a multifunctional, mammalian redox protein , 2002, Redox report : communications in free radical research.

[12]  Yeul-Hong Kim,et al.  Identification of potential lung cancer biomarkers using an in vitro carcinogenesis model , 2008, Experimental & Molecular Medicine.

[13]  Hong Wang,et al.  Protein profiles associated with survival in lung adenocarcinoma , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[14]  C. Dong,et al.  IL-17 family member cytokines: regulation and function in innate immunity. , 2010, Cytokine & growth factor reviews.

[15]  H. Chae,et al.  Peroxiredoxin‐I is an autoimmunogenic tumor antigen in non‐small cell lung cancer , 2005, FEBS letters.

[16]  G. Schmitz,et al.  Cloning and characterization of a novel apolipoprotein A-I binding protein, AI-BP, secreted by cells of the kidney proximal tubules in response to HDL or ApoA-I. , 2002, Genomics.

[17]  J. Roder,et al.  Establishment of a human large cell lung tumor line (QU‐DB) with metastatic properties in athymic mice , 1986, Cancer.

[18]  Zhuchu Chen,et al.  Triosephosphate isomerase and peroxiredoxin 6, two novel serum markers for human lung squamous cell carcinoma , 2009, Cancer science.

[19]  J. Luk,et al.  Proteomics of hepatocellular carcinoma: serum vimentin as a surrogate marker for small tumors (, 2010, Journal of proteome research.

[20]  Kai-Ping Chang,et al.  Cell secretome analysis using hollow fiber culture system leads to the discovery of CLIC1 protein as a novel plasma marker for nasopharyngeal carcinoma. , 2009, Journal of Proteome Research.

[21]  R. H. Eaton,et al.  Alkaline Orthophosphatase and Inorganic Pyrophosphatase Activities in Human Serum , 1967, Nature.

[22]  N. Ikewaki,et al.  High serum glyceraldehyde-3-phosphate dehydrogenase levels in patients with liver cirrhosis. , 2002, Hepatology research : the official journal of the Japan Society of Hepatology.

[23]  R. Ueda,et al.  Serum glutathione s‐transferase‐π level as a tumor marker for non‐small cell lung cancer. Potential predictive value in chemotherapeutic response , 1994 .

[24]  P. Sham,et al.  Circulating Levels of Adipocyte and Epidermal Fatty Acid–Binding Proteins in Relation to Nephropathy Staging and Macrovascular Complications in Type 2 Diabetic Patients , 2009, Diabetes Care.

[25]  F. Billson,et al.  LOW‐CARBOHYDRATE DIET OPTIC NEUROPATHY , 1977, The Medical journal of Australia.

[26]  A. Pezeshki,et al.  Establishment and characterization of a human large cell lung cancer cell line with neuroendocrine differentiation , 2009, Pathology Oncology Research.

[27]  Khajeelak Chiablaem,et al.  Comparative proteomic analysis of lung cancer cell line and lung fibroblast cell line. , 2009, Cancer genomics & proteomics.

[28]  M. Lai,et al.  The cancer secretome: a reservoir of biomarkers , 2008, Journal of Translational Medicine.

[29]  Gang Huang,et al.  Clinical significance and prognostic value of serum Dickkopf-1 concentrations in patients with lung cancer. , 2009, Clinical chemistry.

[30]  M. Roehrl,et al.  Tissue proteomics reveals differential and compartment-specific expression of the homologs transgelin and transgelin-2 in lung adenocarcinoma and its stroma. , 2009, Journal of proteome research.

[31]  Takashi Takahashi,et al.  Neuroendocrine cancer-specific up-regulating mechanism of insulin-like growth factor binding protein-2 in small cell lung cancer. , 2009, The American journal of pathology.

[32]  K. Eguchi,et al.  Serum levels of cytokines in patients with untreated primary lung cancer. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[33]  E. Brambilla,et al.  Expression of plasminogen activator inhibitors 1 and 2 in lung cancer and their role in tumor progression. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[34]  W. Brück,et al.  Glutamine synthetase in cerebrospinal fluid, serum, and brain: a diagnostic marker for Alzheimer disease? , 1999, Archives of neurology.

[35]  David E. Misek,et al.  Proteomics-based identification of RS/DJ-1 as a novel circulating tumor antigen in breast cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[36]  Chih-Long Chang,et al.  Stress-induced Phosphoprotein 1 as a Secreted Biomarker for Human Ovarian Cancer Promotes Cancer Cell Proliferation* , 2010, Molecular & Cellular Proteomics.

[37]  D. Tai,et al.  Candidate Serological Biomarkers for Cancer Identified from the Secretomes of 23 Cancer Cell Lines and the Human Protein Atlas* , 2010, Molecular & Cellular Proteomics.

[38]  B. Cauwe,et al.  Adenylyl cyclase-associated protein-1/CAP1 as a biological target substrate of gelatinase B/MMP-9. , 2008, Experimental cell research.

[39]  W. Naumnik,et al.  Serum levels of HMGB1, survivin, and VEGF in patients with advanced non-small cell lung cancer during chemotherapy. , 2010, Folia histochemica et cytobiologica.

[40]  H. Beug,et al.  ILEI: a cytokine essential for EMT, tumor formation, and late events in metastasis in epithelial cells. , 2006, Cancer cell.